Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

Biomarker Research

Table 2 Multivariable analysis concerning overall and event-free survival

Factor	Overall Survival		Event-free Survival
Factor	HR [95% CI]	p-value	HR [95% CI]	p-value
Low Risk Karyotype	0.486 [0.287–0.825]	0.007	0.553 [0.374–0.818]	0.003
High Risk Karyotype	1.858 [1.404–2.459]	< 0.001	1.407 [1.088–1.818]	0.009
Higher Age^a	1.034 [1.021–1.047]	< 0.001	1.021 [1.011–1.032]	< 0.001
FLT3-ITD positivity	1.834 [1.376–2.445]	< 0.001	1.430 [1.109–1.843]	0.006
NPM1 mutation	0.527 [0.385–0.723]	< 0.001	0.530 [0.408–0.689]	< 0.001
Logarithmic (to base 10) WBC	1.191 [0.962–1.474]	0.109	1.030 [0.857–1.237]	0.754
Bone Marrow Blast Count at Day 15 after Induction Chemotherapy^b	1.010 [1.005–1.014]	< 0.001	1.028 [1.023–1.033]	< 0.001
Extramedullary Disease	1.203 [0.698–2.076]	0.506	0.888 [0.535–1.476]	0.648
high LOX Expression	0.956 [0.711–1.285]	0.766	1.034 [0.804–1.329]	0.795
Interaction of Extramedullary Disease and high LOX Expression	2.246 [1.106–4.559]	0.025	2.478 [1.264–4.857]	0.008

Table 2 Results of multivariate testing for overall survival and event-free survival including HR, 95% CI and p-values
Abbreviations: HR hazard ratio, 95% CIs 95% confidence interval
^aage as a continuous variable in years
^bbone marrow blast count as a continuous variable in percent

ISSN: 2050-7771